Algeta Completes Sample Size Re-Estimation Of Alsympca Trial
Algeta said that the sample size re-estimation confirmed that the current plan to recruit 750 patients into the Alsympca study will meet the goals originally set for the
The European Commission (EC) has approved an extended use of Johnson & Johnson’s Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r/r MM).
Following the recommendation for regulatory approval under the European decentralised procedure, Toctino has received national regulatory approval in Italy and was accepted for reimbursement. Basilea Pharmaceutica claimed that